Search

Your search keyword '"Allergan PLC -- Product development"' showing total 11 results
Start Over Descriptor "Allergan PLC -- Product development" Journal pharmabiz
11 results on '"Allergan PLC -- Product development"'

1. US FDA approves Allergan's NDA for Durysta for ocular hypertension patients

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Hypertension, Patient compliance, Pharmaceutical industry -- Product development, Bimatoprost -- Product development, Open-angle glaucoma, Industrial research, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc, a leading global pharmaceutical company announced that the US Food and Drug Administration (US FDA) has approved the company's New Drug Application (NDA) for Durysta (bimatoprost implant) 10 [...]

Published
2020

2. Allergan, Editas Medicine begin patient dosing in phase 1/2 trial of CRISPR Medicine AGN-151587 (EDIT-101) to treat LCA1

Subjects
Allergan PLC -- Product development, Clinical trials, Medical research, Pharmaceutical industry -- Product development, Blindness -- Care and treatment, Genetic disorders -- Care and treatment, Genomics, Genetic research, Genes, Health, Pharmaceuticals and cosmetics industries, Oregon Health & Science University
Abstract

Allergan plc, a leading global pharmaceutical company, and Editas Medicine, Inc., a leading genome editing company, announced the treatment of the first patient in the BRILLIANCE clinical trial of AGN-151587 [...]

Published
2020

3. Allergan announces positive phase 3 ACHIEVE I trial results for ubrogepant

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, Periodicals, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc announced that positive results from ACHIEVE I (UBR-MD-01), a robust phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the December [...]

Published
2019

4. Allergan, Molecular Partners present data from phase 3 studies of Abicipar in patients with neovascular wet AMD at AAO m

Subjects
Allergan PLC -- Product development, Clinical trials, Macular degeneration, Ranibizumab, Medical research, Pharmaceutical industry -- Product development, Ophthalmology, Pharmaceuticals and cosmetics industries, American Academy of Ophthalmology
Abstract

Allergan plc, a leading global pharmaceutical company, and Molecular Partners, a clinical-stage biopharmaceutical company, announced two-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with [...]

Published
2019

5. US FDA accepts Allergan's NDA for Bimatoprost SR for patients with open-angle glaucoma/ocular hypertension

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Hypertension -- Care and treatment, Patient compliance, Pharmaceutical industry -- Product development, Bimatoprost -- Product development, Glaucoma -- Care and treatment, Open-angle glaucoma, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc, a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced that the US FDA has accepted the company's New Drug Application (NDA) [...]

Published
2019

6. US FDA accepts Allergan's NDA for ubrogepant for acute treatment of migraine

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Medical research, Migraine -- Drug therapy, Prescriptions (Drugs) -- Product development, Legal fees, Clinical trials, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for ubrogepant for the acute treatment of migraine in adults. The [...]

Published
2019

7. Allergan reports positive 3 month topline results from second phase 3 study of Bimatoprost SR

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc, a leading global pharmaceutical company, announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant for the reduction of [...]

Published
2019

8. US FDA accepts NDA to review Seysara for treatment of moderate to severe acne

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Antiacne agents, Acne -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Seysara (Medication) -- Product development
Abstract

Allergan plc, a leading global pharmaceutical company, and Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of therapies based upon tetracycline chemistry, announced that the US Food [...]

Published
2017

9. US FDA accepts Allergan's sNDA filing for Avycaz

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Communicable diseases -- Care and treatment, Pneumonia -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Avycaz (Medication)
Abstract

Allergan plc, a leading global pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam) for [...]

Published
2017

10. Allergan announces new data from CENTAUR phase 2b study supports continued development of CVC in ongoing phase 3 AURORA trial

Subjects
Allergan PLC -- Product development, Clinical trials, Liver diseases -- Care and treatment, Medical research, Pharmaceutical industry -- Product development, Liver, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc announced top-line results from new data for the CENTAUR phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis [...]

Published
2017

11. Allergan's sNDA for avycaz gets US FDA nod to include new phase III data in patients with cUTI, including pyelonephritis

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pyelonephritis -- Care and treatment, Urinary tract infections -- Care and treatment, Pharmaceutical industry -- Product development, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Allergan plc, a leading global pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) to update the label for [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results